EUVIMEDEUVIMED entdecken
Crossref

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation

Assoziation des Einsatzes von GLP-1-Rezeptoragonisten mit Sicherheitsendpunkten bei Personen mit Opioidkonsumstörung: Emulation eines Target Trials

Tahmid Hussain, Jabed Al Faysal, Pareeta Kotecha iD, Ronald Ramon, Yehua Wang, Jingchuan Guo iD, Md Mahmudul Hasan iD

Diabetes, Obesity and Metabolism · 2026-08 · 28 (8) · 6861-6873

DOI: 10.1111/dom.70867 ↗

Auf einen Blick

Bei Erwachsenen mit Opioidkonsumstörung war der Beginn einer GLP-1-RA-Therapie nicht mit erhöhten gastrointestinalen, renalen, respiratorischen oder psychiatrischen Risiken verbunden. Für Pankreatitis, Insomnie und Angst wurden niedrigere Risiken beobachtet.

Fragestellung

Ist der Beginn eines GLP-1-Rezeptoragonisten bei Personen mit Opioidkonsumstörung mit unerwünschten gastrointestinalen, renalen, respiratorischen oder psychiatrischen Endpunkten assoziiert?

Methode

Retrospektive Kohortenstudie mit Target-Trial-Emulation in MarketScan Commercial Claims and Encounters (2016–2023); Zeit-abhängiges Propensity-Score-Matching; Vergleich von GLP-1-RA-Nutzer:innen mit Nicht-Nutzer:innen.

Ergebnisse

Je Endpunkt 1.472 bis 2.329 GLP-1-RA-Nutzer:innen und ebenso viele Nicht-Nutzer:innen. Pankreatitis: aHR 0,65 (95 %-KI 0,45–0,93); Insomnie: 0,78 (0,68–0,89); Angst: 0,76 (0,67–0,86).

Einschränkungen

Mögliche Residualkonfundierung kann nicht ausgeschlossen werden.

Schlussfolgerung der Autor:innen

Der Beginn von GLP-1-RAs war nicht mit erhöhten unerwünschten gastrointestinalen, renalen, respiratorischen oder psychiatrischen Endpunkten assoziiert und mit niedrigeren Risiken für Pankreatitis, Insomnie und Angst verbunden.

Kernaussagen

  • Keine erhöhten gastrointestinalen, renalen, respiratorischen oder psychiatrischen Risiken
  • Niedrigeres Risiko für Pankreatitis: aHR 0,65 (95 %-KI 0,45–0,93)
  • Niedrigere Risiken für Insomnie und Angst

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 18.05.2026. Verfasst von Tahmid Hussain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Opioid-Related Disorders, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) initiation and adverse gastrointestinal, renal, respiratory and psychiatric outcomes among individuals with opioid use disorder (OUD). Materials and Methods This retrospective cohort study was conducted using the MarketScan Commercial Claims and Encounters database (2016–2023) following a target trial emulation framework. Participants were aged 18 years or older with OUD and eligible for GLP‐1 RA treatment for type 2 diabetes or obesity. Ten prespecified safety outcomes were assessed. For each prespecified outcome, separate analytic cohorts of GLP‐1 RA users and non‐users were created based on time‐conditional propensity score matching. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated comparing GLP‐1 RA users with non‐users, with follow‐up until outcome occurrence, disenrollment or end of the study period (December 2023), whichever came first.

Results

For each prespecified outcome, the size of the matched cohorts varied from 1472 to 2329 GLP‐1 RA users (and an equal number of non‐users), depending on outcome‐specific eligibility criteria. For the gastrointestinal outcomes, GLP‐1 RA use was associated with a lower risk of pancreatitis (aHR, 0.65; 95% CI, 0.45–0.93), with no increased risk of gastroparesis. No increased risks were observed for renal (AKI) or respiratory (aspiration pneumonitis) outcomes. Among psychiatric outcomes, lower risks were observed for insomnia (0.78; 0.68–0.89) and anxiety (0.76; 0.67–0.86), with no increased risk for depression, stress‐related disorders, eating disorders and suicidal behaviour or ideation. Findings were generally consistent across subgroups stratified by age, sex and type 2 diabetes status.

Conclusions

In a large cohort of commercially insured individuals with OUD, GLP‐1 RA initiation was not associated with increased adverse gastrointestinal, renal, respiratory or psychiatric outcomes and was associated with lower risks of pancreatitis, insomnia and anxiety. While the possibility of residual confounding cannot be excluded, these data support the safety of GLP‐1 RAs when used for approved indications in patients with OUD and inform ongoing repurposing efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsOpioid-Related DisordersDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultObesity

Stichwörter der Autor:innen

GLP‐1 receptor agonistsdrug repurposingopioid use disorderreal‐world evidencesafety profile

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, Florida, USA.
  • Department of Pharmacy Practice, Purdue University College of Pharmacy, Indianapolis, Indiana, USA.
  • Regenstrief Institute, Indianapolis, Indiana, USA.
  • Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.
  • Department of Information Systems and Operations Management, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Pareeta Kotecha, Jingchuan Guo, Md Mahmudul Hasan

Zitieren

APA

Hussain, T., Al Faysal, J., Kotecha, P., Ramon, R., Wang, Y., Guo, J., & Hasan, M. M. (2026). Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation. Diabetes, Obesity and Metabolism, 28(8), 6861-6873. https://doi.org/10.1111/dom.70867

Vancouver

Hussain T, Al Faysal J, Kotecha P, Ramon R, Wang Y, Guo J, et al. Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation. Diabetes, Obesity and Metabolism. 2026;28(8):6861-6873. doi:10.1111/dom.70867

BibTeX
@article{Hussain2026,
  author = {Hussain, Tahmid and Al Faysal, Jabed and Kotecha, Pareeta and Ramon, Ronald and Wang, Yehua and Guo, Jingchuan and Hasan, Md Mahmudul},
  title = {Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {6861--6873},
  doi = {10.1111/dom.70867}
}
Kostenlos starten →